The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX ...

Biotech stocks are among the few industry groups producing breakouts and buyable stocks in an uncertain market. Vertex stock ...

Both stocks should deliver excellent returns to investors patient enough to hold through volatility. Equity markets started ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

Journavx (suzetrigine), Vertex’s non-opioid NaV1.8 pain signal inhibitor, for the treatment of moderate-to-severe acute pain, was approved by the FDA in January 2025. At the fourth-quarter ...

The stock’s price increase is mainly because the company gained approval for two new products, its novel non-opioid pain medicine Journavx (suzetrigine ... in price. Vertex holds a dominant ...